Floatz logo

Recombinant Fowlpox-CEA(6D)

Adenocarcinoma of the Gallbladder

National Cancer Institute (NCI)Phase 1Dormant
CC
44/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
29/ 100
Competitive Position
95/ 100

Competitive context

4 Active assets in the Adenocarcinoma of the Gallbladder cohort.

Asset / SponsorPhaseRating
Irinotecan
Georgetown University
Phase 3BB
Atezolizumab
Georgetown University
Phase 3B
Bortezomib
National Cancer Institute (NCI)
Phase 2CCC
azd6244
National Cancer Institute (NCI)
Phase 2CCC
mk-2206
National Cancer Institute (NCI)
Phase 2CCC

View all 14 →

Same molecule, other indications

Recombinant Fowlpox-CEA(6D) is also rated in:

breast cancerDormant
CC
Indicative ·
47 / 100
View asset →
metastatic neoplasmDormant
CC
Indicative ·
45 / 100
View asset →
Adult Solid NeoplasmDormant
CC
Indicative ·
44 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →